KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Construction in Progress: 2010-2024

Historic Construction in Progress for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $245,000.

  • Nektar Therapeutics' Construction in Progress fell 66.85% to $245,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $245,000, marking a year-over-year decrease of 66.85%. This contributed to the annual value of $245,000 for FY2024, which is 66.85% down from last year.
  • Nektar Therapeutics' Construction in Progress amounted to $245,000 in FY2024, which was down 66.85% from $739,000 recorded in FY2023.
  • Nektar Therapeutics' Construction in Progress' 5-year high stood at $7.2 million during FY2021, with a 5-year trough of $245,000 in FY2024.
  • For the 3-year period, Nektar Therapeutics' Construction in Progress averaged around $1.2 million, with its median value being $739,000 (2023).
  • Its Construction in Progress has fluctuated over the past 5 years, first spiked by 52.40% in 2021, then slumped by 70.79% in 2023.
  • Nektar Therapeutics' Construction in Progress (Yearly) stood at $4.7 million in 2020, then surged by 52.40% to $7.2 million in 2021, then plummeted by 64.68% to $2.5 million in 2022, then crashed by 70.79% to $739,000 in 2023, then crashed by 66.85% to $245,000 in 2024.